Publication of results of pre-clinical studies support efficacy and drug delivery mechanism potential of renovorx's tamp™ therapy platform to improve targeted cancer drug treatment delivery

Los altos, calif.--(business wire)--renovorx, inc. (“renovorx” or the “company”) (nasdaq: rnxt), a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, today announced a publication of pre-clinical studies supporting the efficacy and drug delivery mechanism of renovorx's trans-arterial micro-perfusion (“tamp”) therapy platform. the data was published online in the peer-reviewed journal of vascular interventional radiolog.
RNXT Ratings Summary
RNXT Quant Ranking